On March 9, 1998, Shenzhen Saibainuo Gene Technology Co., Ltd. was officially established.

On December 28, 1998, the State Food and Drug Administration approved "recombinant human p53 adenovirus injection" to enter Phase I clinical trials. In January 1999, the National Ministry of Science and Technology listed the "Recombinant Human p53 Adenovirus Injection" project as a pilot development project in the biotechnology field of the 863 Plan.

In November 1999, Shenzhen City listed the "Recombinant Human p53 Adenovirus Injection" project as a key industrialization project in Shenzhen City. On October 7, 2000, the State Food and Drug Administration approved "Recombinant Human p53 Adenovirus Injection" to enter Phase II clinical trials.

In July 2000, the National Ministry of Science and Technology listed the "Recombinant Human p53 Adenovirus Injection" project into the National Science and Technology Small and Medium-sized Enterprises Technology Innovation Fund project. In December 2001, the Ministry of Science and Technology included the "Recombinant Human p53 Adenovirus Injection" project in the national science and technology research plan.

In December 2001, the production plant for gene therapy products was built in Shenzhen High-tech Industrial Park. On July 3, 2002, "Recombinant Human p53 Adenovirus Injection" obtained the production process invention patent issued by the State Intellectual Property Office (Patent No.: ZL 98 1 23346.5).

On August 16, 2002, the State Food and Drug Administration approved the establishment of a new drug "Recombinant Human p53 Adenovirus Injection Production Workshop" by Saibainuo Company.

In November 2002, the "Recombinant Human p53 Adenovirus Injection" project was included in the 15th National Major Science and Technology Project by the Ministry of Science and Technology.

On November 22, 2002, it obtained the "Drug Production License" issued by the Guangdong Provincial Food and Drug Administration. On July 9, 2003, Dr. W. French Anderson, the “Father of Gene Therapy”, was hired as a consultant to Sabiono.

In July 2003, the new restructuring of Saibainuo Company was completed, with a registered capital of 48.19 million yuan.

On October 16, 2003, "Recombinant Human p53 Adenovirus Injection" (registered trade name: Jin Yousheng) obtained the Class I New Drug Certificate for Biological Products approved by the State Food and Drug Administration. On January 20, 2004, "Recombinant Human p53 Adenovirus Injection" (registered trade name: Jin Yousheng) obtained the production approval document approved by the State Food and Drug Administration.

On March 11, 2004, the production workshop of "Recombinant Human p53 Adenovirus Injection" (registered trade name: Jin Yousheng) obtained the "Drug GMP Certificate" issued by the State Food and Drug Administration.

On October 13, 2004, the foundation stone of Saibainuo gene therapy drug production base was grandly laid in Shenzhen High-tech Industrial Park.

On October 22, 2004, our company's project "The relationship between p53 gene variation and clinical efficacy in Jinyousheng clinical trial patients" was officially approved by the Ministry of Science and Technology to be included in the National Key Basic Research Development Plan (973 Plan). In June 2006, it won the "Global Enterprise Capital Innovation Award" and was personally presented by Singapore President S.R. Nathan.

In October 2006, Benda Pharmaceutical Co. acquired approximately 68% of the company's equity and reorganized the company's board of directors with Mr. Peng Zhaohui. On January 22, 2007, the "China-Japan Cooperation in Research and Development of AIDS Gene Therapy Vaccine" project was signed.

On May 25, 2007, Saibainuo Company obtained two new invention patents granted by the State Intellectual Property Office of the People's Republic of China and the State Intellectual Property Office.

On June 25, 2007, 20 companies including Shenzhen Saibainuo Gene Technology Co., Ltd. won the honorary title of “Shenzhen Intellectual Property Advantage Enterprises”.

In November 2007, Lindsey Balsum, a senior reporter from British TV channel 4, went to Sabernac, the Oncology Department of Shenzhen Second Hospital and Beijing Haidian on the topic of the safety and effectiveness of "Jinamasheng" treatment. Interview at the hospital's gene therapy center. On January 22, 2008, the "China-Japan Cooperation in Research and Development of AIDS Gene Therapy Vaccine" project was signed. 2008

On December 15, 2008, the company's Science and Technology Expert Committee was established, and academicians Zeng Yixin, Wu Zuze, Sun Yan, Wei Yuquan, and Professor Huang Wenlin, authoritative experts in the field of gene therapy in my country, were appointed as the company's science and technology expert committee. For the first term of membership, Academician Zeng Yixin is the chairman. Wu Zuze, a senior academician of the Chinese Academy of Sciences, gave a special message to Saibainuo Company: to establish a scientific and technological strategic platform and build a characteristic gene industry.

On December 11, 2008, the company's president Xu Wei was listed on the "Shenzhen Top 100" list and won the title of "Shenzhen's 100 Outstanding Entrepreneurs in the 30 Years of China's Reform and Opening Up".